SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that it has received a 2015 “Best of What’s New” Award for its 3D bioprinted kidney tissue from Popular Science magazine, recognizing it as one of the 100 Greatest Innovations of the Year.
"Organovo is proud to be named a top health innovator for this year by Popular Science, a leading science and technology magazine,” said Keith Murphy, chairman and chief executive officer of Organovo. “The past year has been important for us as we successfully launched our exVive3D TM Human Liver Tissue and continue to grow the market for bioprinted tissues in drug research and development. We’re excited to advance our next portfolio offering of 3D human kidney tissue.”
“The Best of What’s New awards honor the innovations that surprise and amaze us—those that challenge our view of what’s possible in the future,” said Cliff Ransom, Editor-in-Chief of Popular Science. “The award is Popular Science’s top prize, and the 100 winners—chosen from among thousands of nominees—are each a revolution in their respective fields.”
Organovo's 3D bioprinting enables the reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. The Company is building a number of 3D tissue models for research and drug discovery applications, as well as working to fulfill their vision of building human tissues for surgical therapy and transplantation. Organovo is also on track to bring its 3D bioprinted human kidney tissue to the broader commercial market in 2016 for use in toxicology and other preclinical drug testing.
The Company has announced collaborations with L’Oreal to develop 3D printed skin tissue for product evaluation and other areas of advanced research, with Merck to develop multiple custom tissue models for drug development, and with the Yale School of Medicine to develop 3D organ tissues for surgical transplantation research.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company recently launched its initial product of the planned exVive3D portfolio offering, the exVive3D Human Liver Tissue for use in toxicology and other preclinical drug testing. Additional products are in development, with the anticipated release of the exVive3D Human Kidney Tissue scheduled for the third quarter of calendar year 2016. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous other media outlets. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com .
About Best of What's New Each year, the editors of Popular Science review thousands of products in search of the top 100 tech innovations of the year—breakthrough products and technologies that represent a significant leap in their categories. The winners, the Best of What's New, are awarded inclusion in the much-anticipated December issue of Popular Science, the most widely read issue of the year since the debut of Best of What's New in 1988. Best of What’s New awards are presented to 100 new products and technologies in 12 categories: Automotive, Aviation, Computing, Engineering, Gadgets, Green, Entertainment, Security, Software, Home, Health and Recreation.
About Popular Science Founded in 1872, Popular Science is the world’s largest science and technology magazine; with a circulation of 1.3 million and 6.8 million monthly readers. Each month, Popular Science reports on the intersection of science and everyday life, with an eye toward what’s new and why it matters. Popular Science is published by Bonnier Active Media, a subsidiary of Bonnier Corporation.
Investor Contact: Steve Kunszabo Organovo Holdings, Inc. +1 (858) 224-1092 skunszabo@organovo.com Press Contact: Suzanne Clancy, Ph.D. Little Dog Communications +1 (858) 480-2410 suzanne@litldog.com
